Central precocious puberty (CPP) is a condition in which puberty starts at a very young age, usually before the age of 8 in girls and before the age of 9 in boys. The global CPP treatment market is primarily driven by the increasing prevalence of the condition, which is attributed to factors such as obesity and environmental pollutants. The major players operating in the market include pharmaceutical companies such as AbbVie Inc., Pfizer Inc., Ferring Pharmaceuticals, Inc., Ipsen Biopharmaceuticals, Inc., and Novartis AG. The market is characterized by the development of new and innovative treatments, including hormone therapies and gene therapies. However, the high cost of treatment and the limited availability of specialized healthcare facilities in some regions may hinder market growth. Increasing awareness about the condition and the availability of effective treatments are expected to further drive market growth.
The Global Central Precocious Puberty Market is estimated to be valued at US$ 1,595.2 Mn in 2022 and expected to exhibit a CAGR of 7.9% over the forecast period (2022-2030).
Leading Companies in the Central Precocious Puberty Industry:
1. Teva Pharmaceutical Industries Ltd.
Founded in 1901, Teva Pharmaceutical Industries Ltd. is a multinational pharmaceutical company headquartered in Petah Tikva, Israel. The company operates in over 60 countries worldwide and is known for its wide range of generic and specialty medicines. Teva is committed to providing affordable healthcare solutions and has a strong focus on research and development. In addition to its pharmaceutical business, Teva also has a presence in the medical device industry. In March, 2023 Teva Pharmaceutical Industries Ltd. announced that a respiratory patient monitoring program using data from Teva’s Digihaler System has been implemented within California’s Desert Oasis Healthcare (DOHC) system.
2. AbbVie Inc.
Founded in 2013 as a spin-off from Abbott Laboratories, AbbVie Inc. is an American pharmaceutical company headquartered in North Chicago, Illinois. The company operates in over 175 countries worldwide and specializes in the research and development of innovative therapies for a range of diseases, including rheumatology, gastroenterology, and oncology. AbbVie is dedicated to improving the lives of patients around the world and has a strong focus on sustainable healthcare practices. In February, 2023 AbbVie and Capsida Biotherapeutics Inc. announced an expanded strategic collaboration to develop genetic medicines for eye diseases with high unmet need.
3. Arbor Pharmaceuticals, LLC
Founded in 2006, Arbor Pharmaceuticals, LLC is a privately held pharmaceutical company headquartered in Atlanta, Georgia. The company operates in the United States and has a strong focus on the development and commercialization of specialty pharmaceuticals in various therapeutic areas, including cardiovascular, endocrinology, and pediatrics. Arbor Pharmaceuticals is committed to improving patient outcomes through innovative and affordable therapies. In September, 2022 Azurity Pharmaceuticals, Inc., a pharmaceutical company focused on developing innovative dose-forms and formulations of products to serve the needs of overlooked patients, announced today that the U.S. Food and Drug Administration (FDA) has approved Konvomep™ (omeprazole and sodium bicarbonate for oral suspension).
4. Pfizer Inc.
Founded in 1849, Pfizer Inc. is an American multinational pharmaceutical company headquartered in New York City. The company operates in over 150 countries worldwide and is known for its broad range of prescription and over-the-counter medicines. Pfizer is committed to improving healthcare through innovative research and development and has a strong focus on vaccines, oncology, and rare diseases. In January, 2023 Gero announced that it has entered into a research collaboration with Pfizer to apply Gero’s machine learning technology platform to discover potential therapeutic targets for fibrotic diseases using large-scale human-based data.
5. Tolmar Pharmaceuticals, Inc.
Founded in 2007, Tolmar Pharmaceuticals, Inc. is a privately held pharmaceutical company headquartered in Fort Collins, Colorado. The company operates in the United States and has a strong focus on developing and commercializing generic and specialty pharmaceuticals in various therapeutic areas, including urology, oncology, and dermatology. Tolmar Pharmaceuticals is committed to improving patient care through high-quality, affordable medicines. In October, 2022 Tolmar Pharmaceuticals, Inc., a fully integrated pharmaceutical company, through its affiliate, Tolmar, Inc., today announced the acquisition of all rights to JATENZO® from Clarus Therapeutics Holdings, Inc. and its wholly-owned subsidiary Clarus Therapeutics, Inc. (collectively, "Clarus").
6. Endo International plc
Founded in 1997, Endo International plc is an Irish-American specialty pharmaceutical company headquartered in Dublin, Ireland. The company operates in over 60 countries worldwide and specializes in the research, development, and commercialization of treatments for pain, urology, and oncology. Endo International is committed to improving patient outcomes through innovative and high-quality medicines.
7. Ipsen Pharma
Founded in 1929, Ipsen Pharma is a French multinational pharmaceutical company headquartered in Boulogne-Billancourt, France. The company operates in over 115 countries worldwide and specializes in the research, development, and commercialization of treatments for rare diseases, neurology, and endocrinology. Ipsen Pharma is committed to improving patient care through innovative therapies and sustainable healthcare practices.
8. Debiopharm Group
Founded in 1979, Debiopharm Group is a Swiss biopharmaceutical company headquartered in Lausanne, Switzerland. The company operates in over 100 countries worldwide and specializes in the research, development, and commercialization of innovative treatments for oncology, infectious diseases, and dermatology. Debiopharm Group is committed to improving patient outcomes through personalized medicine and sustainable healthcare practices.
9. Sun Pharmaceutical Industries Limited
Founded in 1983, Sun Pharmaceutical Industries Limited is an Indian multinational pharmaceutical company headquartered in Mumbai, India. The company operates in over 100 countries worldwide and specializes in the research, development, and commercialization of generic and specialty pharmaceuticals in various therapeutic areas, including psychiatry, neurology, and gastroenterology. Sun Pharmaceutical Industries Limited is committed
*Definition- Central precocious puberty (CPP) is a condition in which a child's body begins to develop into that of an adult too soon, due to early activation of the hypothalamic-pituitary-gonadal axis.
